| [1] |
Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer [ J]. Biochim Biophys Acta, 1994,1198(2-3):165-184.
|
| [2] |
Slamon DJ,Clark GM,Wong SG,et al. Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene [J]. Science, 1987,235 (4785):177-182.
|
| [3] |
Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer[J]. Science,1989,244 (4905):707-712.
|
| [4] |
Osborne CK, Shou J, Massarweh S, et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer [J]. Clin Cancer Res,2005,11 (2 Pt 2):865s-870s.
|
| [5] |
Knuefermann C, Lu Y, Liu B, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells[J]. Oncogene,2003,22 (21):3205-3212.
|
| [6] |
Slamon D, Eiermann W, Robert N, et al. A adjuvant trastuzumab in HER2-positive breast cancer [J]. N Engl J Med,2011,365 (14):1273-1283.
|
| [7] |
Hudis CA. Trastuzumab--mechanism of action and use in clinical practice [J]. N Engl J Med,2007,357 (1):39-51.
|
| [8] |
Baselga J, Perez EA, Pienkowski T, et al. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer[J]. Oncologist,2006,11 Suppl 1:4-12.
|
| [9] |
Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer:NSABP B-31[J]. J Clin Oncol,2005,23 (31):7811-7819.
|
| [10] |
Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J]. J Clin Oncol,2014,32 (33):3744-3752.
|
| [11] |
Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial[J]. Lancet,2013,382 (9897):1021-1028.
|
| [12] |
Zardavas D,Fouad TM,Piccart M. Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015 [J].Breast,2015,24 Suppl 2: S143-148.
|
| [13] |
Slamon D, Swain S, Buyse M, et al. BETH: a randomized phase Ⅲ study evaluating adjuvant bevacizumab added to Trastuzumab/Chemotherapy for treatment of HER2 + early breast cancer [ EB/OL]. [2014-12-05 ]. http:/ /refhub.elsevier.com/S0960-9776(15)00172-1/sref22.
|
| [14] |
Piccart-Gebhart MJ, Holmes AP, Baselga J, et al. First results from the phase ⅢALTTO trial (BIG 2-06; NCCTG[Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC) [EB/OL]. [2014-12-05].http:/ /meetinglibrary.asco.org/content/128258-144.
|
| [15] |
U.S. National Institutes of Health. Study evaluating the effects of neratinib after adjuvant trastuzumab in women with early stage breast cancer (ExteNET)[EB/OL]. [2014-12-05].http:/ /clinicaltrials.gov/show/NCT00878709.
|
| [16] |
Feldinger K, Kong A. Profile of neratinib and its potential in the treatment of breast cancer[J]. Breast Cancer (Dove Med Press),2015,7:147-162.
|
| [17] |
Mates M, Fletcher GG, Freedman OC,et al. Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline [J]. Curr Oncol, 2015,22 (Suppl 1): S114-122.
|
| [18] |
Welslau M, Dieras V, Sohn JH, et al. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine ( T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer [J]. Cancer,2014,120 (5):642-651.
|
| [19] |
Hoffman-La R. A study of trastuzumab emtasine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE)[EB/OL]. [2014-12-05]. http:/ /clinicaltrials. gov/show/NCT01772472.
|
| [20] |
Joensuu H,Bono P,Kataja V,et al. Fluorouracil,epirubicin,and cyclophosphamide with either docetaxel or vinorelbine,with or without trastuzumab,as adjuvant treatments of breast cancer:final results of the FinHer Trial [J]. J Clin Oncol, 2009,27 (34):5685-5692.
|
| [21] |
Purmonen TT,Pankalainen E,Turunen JH,et al. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial[J].Acta Oncol,2011,50 (3):344-352.
|
| [22] |
Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE):a randomised phase 3 trial[J].Lancet Oncol,2013,14 (8):741-748.
|
| [23] |
Kramar A, Bachelot T, Madrange N, et al. Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial[J]. Ann Oncol,2014,25 (8):1563-1570.
|
| [24] |
Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer [J]. N Engl J Med,2015,372 (2):134-141.
|
| [25] |
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort[J]. Lancet Oncol,2014,15 (6):640-647.
|
| [26] |
Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J]. Lancet,2012,379 (9816):633-640.
|
| [27] |
Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer(NeoSphere): a randomised multicentre, open-label, phase 2 trial[J]. Lancet Oncol,2012,13 (1):25-32.
|
| [28] |
Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015[J]. Ann Oncol, 2015, 26(8):1533-1546.
|
| [29] |
Joensuu H,Kellokumpu-Lehtinen PL,Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer [J]. N Engl J Med,2006,354 (8):809-820.
|
| [30] |
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer [J]. N Engl J Med,2005,353 (16):1659-1672.
|
| [31] |
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer[J]. N Engl J Med,2005,353 (16):1673-1684.
|
| [32] |
Costa RB, Kurra G, Greenberg L, et al. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer[J]. Ann Oncol,2010,21(11):2153-2160.
|
| [33] |
Jitawatanarat P, O'Connor TL, Kossoff EB, et al. Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancer[J]. J Breast Cancer, 2014,17 (4):356-362.
|
| [34] |
Pivot X, Suter T, Nabholtz JM, et al. Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phaseⅢstudy[J]. Eur J Cancer,2015,51(13):1660-1666.
|
| [35] |
Loibl S, von Minckwitz G, Schneeweiss A, et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2(her2) therapy in primary HER2-overexpressing breast cancer[J]. J Clin Oncol,2014,32 (29):3212-3220.
|
| [36] |
Pogue-Geile KL, Song N, Jeong JH, et al. Intrinsic subtypes,PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial[J]. J Clin Oncol,2015,33 (12):1340-1347.
|
| [37] |
Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial[J]. Ann Oncol,2014,25(8):1544-1550.
|